Aleks joined the Bactolife™ Board of Directors in May 2021
Aleks Engel is a partner with Novo Holdings based in Boston. He joined Novo Holdings in 2014 in Copenhagen and has since 2018 led anti-infective investment activities (the REPAIR Impact Fund and a board position in the AMR Action Fund). Aleks previously worked in business development for Baxter International and Pfizer in the United States and China and prior to that was a consultant with McKinsey and Company. He obtained his Ph.D. in biochemical engineering and M.S. in chemical engineering from M.I.T. Aleks grew up on a farm in Denmark.